Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 9—September 2004


SARS Antibody Test for Serosurveillance

Po-Ren Hsueh*1, Chuan-Liang Kao*1, Cun-Nan Lee*, Li-Kuan Chen†, Mei-Shian Ho‡, Charles Sia§¶, Xin De Fang§, Shugene Lynn¶, Tseng Yuan Chang§, Shi Kau Liu§, Alan M. Walfield§, and Chang Yi Wang§¶Comments to Author 
Author affiliations: *National Taiwan University College of Medicine, Taipei, Taiwan; †Tsu Chi University, Hualien, Taiwan; ‡Academia Sinica, Taipei, Taiwan; §United Biomedical, Inc., Hauppauge, New York, USA; ¶United Biomedical, Inc. Asia, Hsin Chu, Taiwan; 1Drs. Hsueh and Kao contributed equally to this article.

Main Article

Table 2

Sensitivity and specificity of peptide-based ELISAa

Source of samples Total no. ELISA+ ELISA–
Blood donors (Gulf Coast Regional Blood Bank, USA) 1,390 0 1,390
Blood-transmitted pathogen panel (various blood banks, USA) 52 0 52
Interference panel (BBI) 41 0 41
Confirmed SARS (TW CDC) 69 69 0
Influenza patients (NTU) 10 0 10
Influenza vaccinees (NTU) 16 0 16
Rubella patients (NTU) 10 0 10
EBV patients (NTU) 9 0 9
Mycoplasma (NTU) 5 0 5
CMV patients (NTU) 8 0 8

aELISA, enzyme-linked immunosorbent assay; NTU, National Taiwan University; BBI, Boston Biomedica Inc (Boston, MA); TW CDC, Taiwan Center for Disease Control; CMV, cytomegalovirus; EBV, Epstein-Barr virus.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO